Flavonoids May Rewrite Cancer Epigenetics, but Human Evidence Still Lags

Flavonoids, the polyphenolic compounds abundant in many plant-derived foods, are drawing renewed scientific attention for their capacity to influence epigenetic processes implicated in disease onset. A narrative review published in Epigenetics & Chromatin examines preclinical and clinical evidence on how these compounds modulate the principal epigenetic pathways—DNA methylation, histone modification, and non-coding RNAs—that alter gene expression without changing the underlying DNA sequence. As cancers develop and spread, changes in these pathways are frequently observed, making them attractive targets for dietary and pharmacological intervention.

The review reports that, mainly in cell-line and animal models, specific flavonoids including quercetin, apigenin, luteolin, and genistein have been shown to modulate histone acetyltransferases, histone deacetylases, DNA methyltransferases, selected non-coding RNAs, and chromatin-remodeling pathways. These molecular interactions produce downstream effects on gene expression programs related to tumor growth, suggesting a mechanistic basis for the antitumor observations frequently described in laboratory studies. Because the evidence base is dominated by in vitro and animal work, the authors emphasize that the findings remain preclinical in character.

Curcumin, a polyphenol that is not a flavonoid, is treated separately in the review where clinical data are considered. Clinical trials of curcumin have reported antitumor outcomes, but the review notes a critical limitation: those trials did not measure epigenetic endpoints. As a result, the mechanistic findings generated in laboratory systems have not yet been validated in patients, and the clinical relevance of the epigenetic modulation observed in cell and animal models remains unconfirmed.

Several challenges persist across the field, according to the review. Limited bioavailability of flavonoids complicates the translation of laboratory concentrations to achievable human exposures, and inconsistencies between experimental and clinical results further temper enthusiasm. The authors conclude that clinical studies incorporating epigenetic biomarker endpoints are needed before any therapeutic role for flavonoids in cancer can be established, framing the current state of knowledge as promising but preliminary.

Subject of Research: How flavonoids modulate DNA methylation, histone modification and non-coding RNAs in cancer, based on preclinical and clinical evidence.

Article Title: Epigenetic and non-coding RNA modulation by flavonoids in cancer: mechanistic insights and therapeutic potential

Article References: Manzoor, M. U., Ayesha, N., Owais, M., Ali, S., Nazir, M. S., Haider, M. S., Afzal, A., Shidane, A. A., & Mohamed, Z. I. (2026). Epigenetic and non-coding RNA modulation by flavonoids in cancer: mechanistic insights and therapeutic potential. Epigenetics & Chromatin. https://doi.org/10.1186/s13072-026-00710-0

Image Credits: AI Generated

DOI: 10.1186/s13072-026-00710-0

Keywords: flavonoids, epigenetics, cancer, DNA methylation, histone modification, non-coding RNAs, quercetin, apigenin, luteolin, genistein, curcumin, bioavailability